CVBio Develops Innovative Oncolytic Adenoviruses to Specifically Target and Destroy Resistant Cancers
CVBio is a biotechnology company developing virus-driven immunotherapies to treat cancer. Its unique platform uses an engineered version of the common cold virus designed to selectively infect and destroy cancer cells while sparing healthy tissue. CVBio’s therapies spark a chain reaction of tumor cell destruction, beginning with targeted viral replication in cancer cells and culminating in a powerful immune response against tumors.
Our Progress
Therapies
CVBio’s virus-driven platform destroys tumors and turns “cold” cancers “hot” for immune response.
Learn MoreDiseases
A pipeline of novel immunotherapies is being developed for the treatment of a variety of aggressive cancers.
Learn MoreClinical Trials
CVBio’s viral immunotherapies are being tested in clinical trials for adults and children with aggressive brain tumors.
Learn MoreNews and Resources
